This nomogram predicts ADT-free survival after MDT in oligorecurrent prostate cancer. While individual-level discrimination was modest, risk-group stratification showed meaningful separation, supporting its potential use in treatment selection.
[Articles] Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort study
The Lancet Oncology | | Timo F W Soeterik, Marcin Miszczyk, Max Peters, Mateusz Bilski, Giulio Francolini, Pietro Garlatti, Luca Nicosia, Filippo Alongi, Maris Mezeckis, Justyna Kociolek, Carlo Greco, Tomasz Techmański, Eline H Huele, Frederik R Teunissen, Paulien G Westhoff, Wessel Vis, Marie A D Haverkort, Jochem R N van der Voort van Zyp, Martijn P W Intven, Joanne M van der Velden, Shahrokh F Shariat, Wietse S C Eppinga
Topics: prostate-cancer, radiation, research